Nyein PP, Borok M, Eriobu N, Kaplan R, et al. A randomised trial to compare dolutegravir plus boosted darunavir versus recommended standard of care antiretroviral regimens in people with HIV-1, whose first-line non-nucleoside reverse transcriptase inhibitor therapy has failed: Final 96-week resul Clin Infect Dis 2025 Jun 27:ciaf346. doi: 10.1093.
PMID: 40577173